categorized as prodrugs currently, and also that during 2008, 33 % of approved small molecular weight drugs were prodrugs [5-7]. The objective of this review is to provide the researchers with a compilation of which carriers would be suitable for prodrug synthesis and what would be their benefi ts. Classifi cation of prodrugs: According to Wermuth prodrugs can be divided into two main categories, bioprecusors and carrierlinked prodrugs [8]. Bioprecursors do not have a promoiety or carrier but yield the active compound upon biotransformation. A bioprecursor prodrug is transformed chemically through hydration (for example, lactones such as some statins), reduction (for example, sulindac, platinum (IV) complexes) or oxidation (for example, dexpanthenol, nabumetone) or metabolically to the active agent [5,9-11]. Carrier-linked prodrugs are for drugs with major drawbacks, which are linked to a nontoxic carrier or promoiety through covalent linkage to change or get